This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Drug-induced myasthenic syndromes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Penicillamine is the key drug that induces a myasthenic syndrome; it is used in the treatment of rheumatoid arthritis and Wilson's disease. It may cause a true myasthenia gravis with detectable circulating antibodies to the acetylcholine receptor. Recovery follows several months after the drug is withdrawn.

Other drugs may interfere with neuromuscular transmission either by pre-synaptic inhibition of the nerve action potential due to inhibition of calcium flux; or may induce a post-synaptic curare like blockade; or may inhibit ionic conductance across the muscle membrane. Drugs implicated include (1):

  • antibiotics - aminoglycosides, tetracyclines, quinine, quinidine; perhaps the 4-quinolone antibiotics such as ciprofloxacin.
  • beta-adrenoreceptor blocking drugs
  • phenytoin
  • lithium
  • phenothiazines

Reference:

  • Newsom-Davis J (1993), Myasthenia gravis and the Lambert-Eaton myasthenic syndrome, Prescribers' Journal, 33(5): 205-11.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.